Abstract
Current outbreaks of SARS-CoV-2 are threatening the health care systems of several countries around the world. The control of SARS-CoV-2 epidemics currently relies on non-pharmaceutical interventions, such as social distancing, teleworking, mouth masks and contact tracing. However, as pre-symptomatic transmission remains an important driver of the epidemic, contact tracing efforts struggle to fully control SARS-CoV-2 epidemics. Therefore, in this work, we investigate to what extent the use of universal testing, i.e., an approach in which we screen the entire population, can be utilized to mitigate this epidemic. To this end, we rely on PCR test pooling of individuals that belong to the same households, to allow for a universal testing procedure that is feasible with the current testing capacity. We evaluate two isolation strategies: on the one hand pool isolation, where we isolate all individuals that belong to a positive PCR test pool, and on the other hand individual isolation, where we determine which of the individuals that belong to the positive PCR pool are positive, through an additional testing step. We evaluate this universal testing approach in the STRIDE individual-based epidemiological model in the context of the Belgian COVID-19 epidemic. As the organisation of universal testing will be challenging, we discuss the different aspects related to sample extraction and PCR testing, to demonstrate the feasibility of universal testing when a decentralized testing approach is used. We show through simulation, that weekly universal testing is able to control the epidemic, even when many of the contact reductions are relieved. Finally, our model shows that the use of universal testing in combination with stringent contact reductions could be considered as a strategy to eradicate the virus.
Competing Interest Statement
Besides his employment at the Hasselt University, JV is part of the investment team of Bioqube Ventures. Bioqube Ventures was not involved in this work, nor does it prosper financially as a result of the current study. The other authors declare that they have no competing interests.
Funding Statement
LW, TV and NH gratefully acknowledge support from the Fonds voor Wetenschappelijk Onderzoek (FWO) (post-doctoral fellowship 1234620N, doctoral fellowship 1S47617N, and RESTORE project - G0G2920N). This work also received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (NH, AT: grant number 682540 - TransMID project; NH, PL: grant number 101003688 - EpiPose project). AT acknowledges support from the special research fund of the University of Antwerp. The resources and services used in this work were provided by the VSC (Flemish Supercomputer Center), funded by the Research Foundation - Flanders (FWO) and the Flemish Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The source code for the simulation model is freely (GPLv3) available on GitHub (universal branch): https://github.com/lwillem/stride. This work generates no new data, except for simulation results, which can be generated from the simulation model source code. All of the data used in our simulation model is mentioned in the reference section.
Data Availability
The source code for the simulation model is freely (GPLv3) available on GitHub (universal branch): https://github.com/lwillem/stride. This work generates no new data, except for simulation results, which can be generated from the simulation model source code. All of the data used in our simulation model is mentioned in the reference section.